Abstract 1997

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients with chronic myeloid leukemia (CML), and is reserved for those who do not respond optimally to tyrosine kinase inhibitors (TKI). Baccarani et al summarized international consensus criteria (ICC) for response to imatinib in first chronic phase (CP) based on time to response; these criteria are used to select alternative therapies including second generation TKIs or HSCT for less than optimal responses. (Baccarani M, et al.J Clin Oncol. 2009; 27:6041–6051). Patients in blast crisis (BC) or accelerated phase (AP) proceed for HSCT if eligible, regardless of optimal response. The prognostic influence of ICC stratification prior to transplant is unknown. We hypothesized the ICC would influence progression after HSCT in patients with CML; in this study we report the impact of this score on transplant outcomes.

Patients and Methods

We performed a retrospective review of patients with CML who underwent a reduced intensity conditioning treatment with busulfan/fludarabine/ATG ± imatinib followed by HSCT. From 1/2000 to 5/2012, 104 patients underwent a matched unrelated or related allogeneic HSCT at the M.D. Anderson Cancer Center. The ICC was applied to patients prior to transplant to denote optimal, suboptimal, or failure of response to a TKI. Demographic and disease-related data were collected, as well as transplant-related covariates. Outcome of interest was progression free survival (PFS) and overall survival (OS), which was estimated using the Kaplan-Meier method.

Results

Patient characteristics are summarized in Table 1, and analysis in Table 2. 36/104 patients received a conditioning treatment containing imatinib and PFS was not statistically different. With median follow up of 36 months (1–126), 62 patients are alive and 30 patients have progressed. Of the 42 deaths, 27(64%) were primarily attributed to leukemia relapse, 3 (9%) infection, 6(17%) graft versus host disease and 6(10%) of other causes. OS was 50% (38–61%) at last follow up and 55% (44–65%) at 36 months. By multivariate analysis, factors predicting progression were: disease status CP1 vs >CP1 (p=0.001) and failure vs optimal/suboptimal response to TKI as defined by ICC (p=0.02). Optimal or suboptimal response defined by ICC was not an independent predictor of the rate of disease progression, OS, or PFS. 77% of patients in the most advanced disease group (AP2/BC/≥CP3) failed to respond to a TKI compared with 44% of patients in CP1 and intermediate group (CP2/AP1/CE), (p=0.006). Age >50 yrs was associated with a trend for higher disease progression, and lower OS and PFS but did not reach significance. There was no impact of ICC stratification in first chronic phase patients; only one patient died or progressed despite 48% identified as failure based on ICC score.

Conclusion

In this single center study with long follow up, we demonstrated ICC score is strongly correlated with disease status at transplant. The latter factor remains the most significant predictor of outcomes. Patients transplanted in first chronic phase have a low rate of progression with allogeneic hematopoietic transplantation regardless of response to TKI therapy based upon ICC score.

Table 1
ICC Score prior to HSCTOptimal (n=21/19%)Suboptimal (n=29/29%)Failure (n=53/52%)
Diagnosis to HSCT (yrs) 2.5 (0.3–20) 2 (0.4–26) 2.8 (0.2–17) 
Age at HSCT (yrs) 44 (14–66) 47 (19–64) 44 (21–69) 
Disease Status Correlated to ICC 
CP1 (23/23%) 5/22% 7/30% 11/48%% 
CP2 (39/38%) 12/31% 13/33%% 14/36% 
≥CP3 (5/5%) 2/40% 1/20% 2/40% 
AP1 (10/10%) 0/0% 4/40% 6/60% 
AP2 (7/7%) 0/0% 1/14% 6/86% 
BC (10/9%) 1/10% 0/0% 9/90% 
CE (9/8%) 1/11% 3/33% 5/56% 
Imatinib vs 2nd gen TKI pre HSCT 11 (52%)/10 17 (58%)/12 27 (50%)/26 
ICC Score prior to HSCTOptimal (n=21/19%)Suboptimal (n=29/29%)Failure (n=53/52%)
Diagnosis to HSCT (yrs) 2.5 (0.3–20) 2 (0.4–26) 2.8 (0.2–17) 
Age at HSCT (yrs) 44 (14–66) 47 (19–64) 44 (21–69) 
Disease Status Correlated to ICC 
CP1 (23/23%) 5/22% 7/30% 11/48%% 
CP2 (39/38%) 12/31% 13/33%% 14/36% 
≥CP3 (5/5%) 2/40% 1/20% 2/40% 
AP1 (10/10%) 0/0% 4/40% 6/60% 
AP2 (7/7%) 0/0% 1/14% 6/86% 
BC (10/9%) 1/10% 0/0% 9/90% 
CE (9/8%) 1/11% 3/33% 5/56% 
Imatinib vs 2nd gen TKI pre HSCT 11 (52%)/10 17 (58%)/12 27 (50%)/26 
View Large
Table 2
PFSOS
Disease Status Groupn=104HR at 3 yr95% CIpHR at 3 yr95% CIp
CP1 23 0.03 0.004–0.2 0.001 0.04 0.006–0.33 0.003 
CP2/AP1/CE 59 0.3 0.1–0.5 <0.001 0.3 0.2–0.7 0.001 
AP2/≥CP3/BC 22 1.0   1.0   
PFSOS
Disease Status Groupn=104HR at 3 yr95% CIpHR at 3 yr95% CIp
CP1 23 0.03 0.004–0.2 0.001 0.04 0.006–0.33 0.003 
CP2/AP1/CE 59 0.3 0.1–0.5 <0.001 0.3 0.2–0.7 0.001 
AP2/≥CP3/BC 22 1.0   1.0   
View Large

Multivariate Analysis adjusting for age & disease status

n=1043 y % KMHRp3 y % KMHRp
CP1 23 95% 0.1 0.02 95% 0.07 0.01 
not CP1/≤50 yrs 49 52% Reference Reference 55% Reference Reference 
not CP1/>50 yrs 32 33% 1.7 0.1 33% 1.8 0.07 
n=1043 y % KMHRp3 y % KMHRp
CP1 23 95% 0.1 0.02 95% 0.07 0.01 
not CP1/≤50 yrs 49 52% Reference Reference 55% Reference Reference 
not CP1/>50 yrs 32 33% 1.7 0.1 33% 1.8 0.07 

CP = Chronic phase; AP = Accelerated phase; BC= Blast crisis; CE = clonal evolution; HR= Hazard ratio; KM = Kaplan Meier.

View Large
graphic
View largeDownload slide
Disclosures:

No relevant conflicts of interest to declare.

Topics:
allogeneic stem cell transplant, protein-tyrosine kinase inhibitor, hematopoietic stem cell transplantation, transplantation, imatinib mesylate, follow-up, accelerated phase, allogeneic hematopoietic stem cell transplant, blast phase, disease progression

This icon denotes a clinically relevant abstract

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2012 by The American Society of Hematology
2012
Sign in via your Institution